Cargando…

Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

BACKGROUND: Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines man...

Descripción completa

Detalles Bibliográficos
Autores principales:	Launay, Odile, Duval, Xavier, Fitoussi, Serge, Jilg, Wolfgang, Kerdpanich, Angkool, Montellano, May, Schwarz, Tino F, Watanveerade, Veerachai, Wenzel, Jürgen J, Zalcman, Gerard, Bambure, Vinod, Li, Ping, Caplanusi, Adrian, Madan, Anuradha, Gillard, Paul, Vaughn, David W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848562/ https://www.ncbi.nlm.nih.gov/pubmed/24041010 http://dx.doi.org/10.1186/1471-2334-13-435

Ejemplares similares

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies
por: Garcia-Sicilia, José, et al.
Publicado: (2015)

Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
por: Nolan, Terry, et al.
Publicado: (2014)

Flexibility of interval between vaccinations with AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial
por: Duval, Xavier, et al.
Publicado: (2012)

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
por: Goll, Johannes B., et al.
Publicado: (2022)

Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination
por: Galson, J. D., et al.
Publicado: (2016)

Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England
por: Winstone, Anne Marie, et al.
Publicado: (2014)

Risk of Narcolepsy Associated with Inactivated Adjuvanted (AS03) A/H1N1 (2009) Pandemic Influenza Vaccine in Quebec
por: Montplaisir, Jacques, et al.
Publicado: (2014)

Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England
por: Yung, Chee-Fu, et al.
Publicado: (2013)

Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
por: Nazareth, Irwin, et al.
Publicado: (2013)

Multi-Centre Observational Study of Transplacental Transmission of Influenza Antibodies following Vaccination with AS03(A)-Adjuvanted H1N1 2009 Vaccine
por: Puleston, Richard, et al.
Publicado: (2013)

Effectiveness of the AS03-Adjuvanted Vaccine against Pandemic Influenza Virus A/(H1N1) 2009 – A Comparison of Two Methods; Germany, 2009/10
por: Uphoff, Helmut, et al.
Publicado: (2011)

Long-term booster schedules with AS03(A)-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults
por: Gillard, Paul, et al.
Publicado: (2014)

Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk
por: Vaarala, Outi, et al.
Publicado: (2014)

Non‐neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system
por: Friel, Damien, et al.
Publicado: (2020)

AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland
por: Nohynek, Hanna, et al.
Publicado: (2012)

AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
por: Khurana, Surender, et al.
Publicado: (2018)

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant
por: Chen, Wilbur H., et al.
Publicado: (2014)

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009
por: Skowronski, Danuta M, et al.
Publicado: (2011)

HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children
por: Leahy, Timothy R, et al.
Publicado: (2014)

Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
por: Madsen, Anders, et al.
Publicado: (2021)

Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination
por: Thebault, Simon, et al.
Publicado: (2015)

Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age
por: Nolan, Terry, et al.
Publicado: (2014)

Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt
por: Dos Santos, Gaël, et al.
Publicado: (2017)

994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells
por: Howard, Leigh, et al.
Publicado: (2018)

Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66(®) cell culture platform
por: Endo, Masafumi, et al.
Publicado: (2020)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials
por: Vaughn, David W, et al.
Publicado: (2014)

Reassessment of the risk of narcolepsy in children in England 8 years after receipt of the AS03-adjuvanted H1N1 pandemic vaccine: A case-coverage study
por: Stowe, Julia, et al.
Publicado: (2020)

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial()
por: Yang, William H., et al.
Publicado: (2013)

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
por: Madan, Anuradha, et al.
Publicado: (2016)

AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets
por: Stadlbauer, Daniel, et al.
Publicado: (2021)

Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: Results of a randomized trial
por: Scheifele, David W., et al.
Publicado: (2013)

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03(A)-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
por: Heijmans, Stéphane, et al.
Publicado: (2011)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
por: Pauksens, Karlis
Publicado: (2013)

Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study
por: Arnheim-Dahlström, Lisen, et al.
Publicado: (2012)

Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials
por: van der Most, Robbert G., et al.
Publicado: (2017)

Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03(A)-Adjuvanted Vaccination in Adults
por: Lasko, Benjamin, et al.
Publicado: (2011)

Evaluation of immune response following one dose of an AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
por: Ikematsu, Hideyuki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gd6hf7ubn9rkv2scr51cpvb2ar